AT530542T - Amino substituted 2- (2,6-dioxopiperidin-3-yl) phthalimides to reduce the tnf-alpha levels - Google Patents

Amino substituted 2- (2,6-dioxopiperidin-3-yl) phthalimides to reduce the tnf-alpha levels

Info

Publication number
AT530542T
AT530542T AT10152833T AT10152833T AT530542T AT 530542 T AT530542 T AT 530542T AT 10152833 T AT10152833 T AT 10152833T AT 10152833 T AT10152833 T AT 10152833T AT 530542 T AT530542 T AT 530542T
Authority
AT
Austria
Prior art keywords
dioxopiperidin
phthalimides
tnf
yl
reduce
Prior art date
Application number
AT10152833T
Other languages
German (de)
Inventor
George W Muller
David Stirling
Roger Chen
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US08690258 priority Critical patent/US5635517B1/en
Priority to US08/701,494 priority patent/US5798368A/en
Priority to US4827897P priority
Application filed by Celgene Corp filed Critical Celgene Corp
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27367302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT530542(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of AT530542T publication Critical patent/AT530542T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/411Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria
AT10152833T 1996-07-24 1997-07-24 Amino substituted 2- (2,6-dioxopiperidin-3-yl) phthalimides to reduce the tnf-alpha levels AT530542T (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US08690258 US5635517B1 (en) 1996-07-24 1996-07-24 Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US08/701,494 US5798368A (en) 1996-08-22 1996-08-22 Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US4827897P true 1997-05-30 1997-05-30

Publications (1)

Publication Number Publication Date
AT530542T true AT530542T (en) 2011-11-15

Family

ID=27367302

Family Applications (4)

Application Number Title Priority Date Filing Date
AT09151443T AT500240T (en) 1996-07-24 1997-07-24 Substituted 2- (2,6-dioxopiperidin-3-yl) phthalimides and oxoisoindolines and method for reducing the tnf-alpha stages
AT02012942T AT460409T (en) 1996-07-24 1997-07-24 Substituted 2- (2,6-dioxopiperidine-3-yl) - phthalimide -1-oxoisoindoline and method for reducing the tnf-alpha mirror
AT10152833T AT530542T (en) 1996-07-24 1997-07-24 Amino substituted 2- (2,6-dioxopiperidin-3-yl) phthalimides to reduce the tnf-alpha levels
AT97936295T AT229521T (en) 1996-07-24 1997-07-24 Substituted 2- (2,6-dioxopiperidin-3-yl) - phthalimides and -1-oxoisoindolines and methods for reducing the tnf-alpha mirror

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT09151443T AT500240T (en) 1996-07-24 1997-07-24 Substituted 2- (2,6-dioxopiperidin-3-yl) phthalimides and oxoisoindolines and method for reducing the tnf-alpha stages
AT02012942T AT460409T (en) 1996-07-24 1997-07-24 Substituted 2- (2,6-dioxopiperidine-3-yl) - phthalimide -1-oxoisoindoline and method for reducing the tnf-alpha mirror

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97936295T AT229521T (en) 1996-07-24 1997-07-24 Substituted 2- (2,6-dioxopiperidin-3-yl) - phthalimides and -1-oxoisoindolines and methods for reducing the tnf-alpha mirror

Country Status (21)

Country Link
EP (4) EP2070920B8 (en)
JP (1) JP4065567B2 (en)
KR (2) KR100534498B1 (en)
CN (1) CN1117089C (en)
AT (4) AT500240T (en)
CA (3) CA2261762C (en)
CZ (3) CZ302378B6 (en)
DE (5) DE122007000079I2 (en)
DK (2) DK0925294T6 (en)
ES (4) ES2529190T3 (en)
FI (1) FI120687B (en)
HK (5) HK1021819A1 (en)
HU (1) HUS1300056I1 (en)
LU (1) LU91359I9 (en)
NL (1) NL300291I2 (en)
NZ (1) NZ333903A (en)
PL (2) PL195916B1 (en)
PT (4) PT925294E (en)
SK (1) SK9199A3 (en)
UA (1) UA60308C2 (en)
WO (1) WO1998003502A1 (en)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US6429221B1 (en) 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
WO1998003502A1 (en) * 1996-07-24 1998-01-29 Celgene Corporation Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and method of reducing tnf-alpha levels
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
DE19703763C1 (en) * 1997-02-01 1998-10-01 Gruenenthal Gmbh Thalidomidanaloge compounds from the class comprising piperidine-2,6-Dione
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
EP1710242A1 (en) * 1997-11-18 2006-10-11 Celgene Corporation Substituted 2-(2,6-Dioxo-3-Fluoropiperidine-3-YL)-Isoindolines and their use to reduce TNF-alpha levels
PT1064277E (en) * 1998-03-16 2005-11-30 Celgene Corp 2- (2,6-dioxopiperidin-3-yl) -isoindolins derivatives, their preparation and their use as inflammatory cytokines inhibitors
KR100712573B1 (en) * 1998-03-16 2007-05-02 셀진 코포레이션 2-2,6-Dioxopiperidin-3-ylIsoindoline Derivatives, their preparation and their use as Inhibitors of Inflammatory Cytokines
WO2000055134A1 (en) 1999-03-18 2000-09-21 Celgene Corporation Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
DE19917195B4 (en) * 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptide for triggering an immune reaction against tumor cells, pharmaceutical compositions containing them, their uses, nucleic acid coding therefor and expression vector containing said nucleic acid
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
JP4242651B2 (en) * 2000-11-30 2009-03-25 ザ チルドレンズ メディカル センター コーポレイション Synthesis of 4-amino-thalidomide enantiomers
CN1487935A (en) * 2000-12-11 2004-04-07 武田药品工业株式会社 Medicinal compositions improved in solubility in water
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
CA2439410C (en) * 2001-02-27 2011-09-06 William D. Figg Analogs of thalidomide as potential angiogenesis inhibitors
PT1423115E (en) * 2001-08-06 2009-07-21 Childrens Medical Center Antiangiogenic activity of nitrogen substituted thalidomide analogs
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
JP2005530784A (en) 2002-05-17 2005-10-13 セルジーン・コーポレーションCelgene Corporation Methods and compositions using immunomodulatory compounds for the treatment and management of cancer and other diseases
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
EP1900369A1 (en) 2002-10-15 2008-03-19 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
US8404717B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
FR2845994B1 (en) * 2002-10-18 2006-05-19 Servier Lab Novel substituted benzo [e] [1,4] oxazino [3,2-g] isoindole derivatives, process for preparing them and pharmaceutical compositions containing the same
US7612096B2 (en) 2003-10-23 2009-11-03 Celgene Corporation Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
WO2004037199A2 (en) * 2002-10-24 2004-05-06 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
NZ540186A (en) * 2002-10-31 2008-03-28 Celgene Corp Composition for the treatment of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CH696542A5 (en) * 2003-07-09 2007-07-31 Siegfried Ltd A process for the preparation of substituted 2,6-dioxopiperidin-3-yl compounds.
CA2537092C (en) * 2003-09-04 2011-08-09 Celgene Corporation Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
CA2538864C (en) 2003-09-17 2013-05-07 The Government Of The United States Of America, As Represented By The Se Cretary Of The Department Of Health And Human Services Thalidomide analogs as tnf-alpha modulators
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
BRPI0509019A (en) 2004-03-22 2007-08-07 Celgene Corp methods for treating, preventing or controlling a skin disorder or disease, for treating, preventing or controlling senile keratosis and for treating or controlling keratosis, pharmaceutical composition, individual unit dosage form, and kit
WO2005112928A1 (en) 2004-05-05 2005-12-01 Celgene Corporation Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
EP2479172B1 (en) 2004-09-03 2013-10-09 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
WO2007005972A1 (en) 2005-06-30 2007-01-11 Celgene Corporation Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
EP1919500A2 (en) 2005-07-13 2008-05-14 Anthrogenesis Corporation Treatment of leg ulcers using placenta derived collagen biofabric
EP1919892B1 (en) 2005-08-31 2013-08-14 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
ES2485316T3 (en) 2005-09-01 2014-08-13 Celgene Corporation Immunological uses of immunomodulatory compounds for vaccines and anti-infectious disease therapy
US20070066512A1 (en) 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
CN1939922B (en) * 2005-09-27 2010-10-13 天津和美生物技术有限公司 5H-thiophene [3,4-C] pyrrole-4,6-diketone derivative for inhibiting cell release tumor necrosis factor
CN101374941A (en) * 2005-12-29 2009-02-25 人类起源公司 Improved composition for collecting and preserving placental stem cells and methods of using the composition
US8426355B2 (en) 2006-03-15 2013-04-23 Theralogics, Inc. Methods of treating muscular wasting diseases using NF-κB activation inhibitors
WO2007136640A2 (en) * 2006-05-16 2007-11-29 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
CL2007002218A1 (en) 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Use of 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl) -piperidine 2,6-dione for the preparation of a medicament useful for the treatment of lymphoma cell layer.
US8105634B2 (en) 2006-08-15 2012-01-31 Anthrogenesis Corporation Umbilical cord biomaterial for medical use
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
NZ575061A (en) * 2006-08-30 2011-10-28 Celgene Corp 5-substituted isoindoline compounds
PT2066656E (en) 2006-09-26 2012-06-28 Celgene Corp 5-substituted quinazolinone derivatives as antitumor agents
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
US8071135B2 (en) 2006-10-04 2011-12-06 Anthrogenesis Corporation Placental tissue compositions
EP2664342A3 (en) 2006-10-06 2014-01-08 Anthrogenesis Corporation Native (telopeptide) placental collagen compositions
ES2523925T3 (en) 2007-09-26 2014-12-02 Celgene Corporation Quinazolinone derivatives substituted in position 6, 7 or 8 and compositions containing them and methods of use thereof
US20090088393A1 (en) * 2007-09-28 2009-04-02 Zomanex, Llc Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
US8263065B2 (en) 2007-09-28 2012-09-11 Anthrogenesis Corporation Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
EP2219627A2 (en) * 2007-11-08 2010-08-25 Celgene Corporation Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction
EP2235213A2 (en) 2007-12-20 2010-10-06 Celgene Corporation Use of micro-rna as a biomarker of immunomodulatory drug activity
CN101959856A (en) * 2008-03-11 2011-01-26 雷迪博士实验室有限公司;雷迪博士实验室公司 Preparation of lenalidomide
US20110060010A1 (en) * 2008-03-13 2011-03-10 Tianjin Hemay Bio-Tech Co., Ltd Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof
CN101531653B (en) * 2008-03-13 2014-07-09 峡江和美药业有限公司 Salts of 3-(4-amino-1-oxo-1,3-dihydro-iso-indol-2-yl)piperdine-2,6-dione and derivatives thereof, polymorph of the salts, preparation and application thereof
WO2009139880A1 (en) * 2008-05-13 2009-11-19 Celgene Corporation Thioxoisoindoline compounds and compositions and methods of using the same
CA2741299C (en) 2008-10-29 2017-03-28 Celgene Corporation Isoindoline compounds for use in the treatment of cancer
DE102008057335A1 (en) 2008-11-14 2010-05-20 Ratiopharm Gmbh Intermediate, useful e.g. as an immunomodulator, for inhibiting the proliferation of certain hematopoietic tumor cells and stimulating erythropoiesis, comprises amorphous lenalidomide and a surface stabilizer
DE102008057284A1 (en) 2008-11-14 2010-05-20 Ratiopharm Gmbh Preparation of tablets containing lenalidomide and adhesion promoter, where the tablets are produced by dry granulation or direct compression, useful e.g. for stimulating erythropoiesis and as an immunomodulator
US9045453B2 (en) 2008-11-14 2015-06-02 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
DE102008057285A1 (en) 2008-11-14 2010-05-20 Ratiopharm Gmbh New intermediate comprising lenalidomide and matrix material, in the form of a solid solution, useful e.g. as immunomodulatory drug, to inhibit proliferation of hematopoietic tumor cells and promote T-cell and natural killer cell immunity
CN102245023B (en) * 2008-11-14 2015-05-13 康塞特医药品有限公司 Substituted dioxopiperidinyl phthalimide derivaties
EP2396312A1 (en) 2009-02-11 2011-12-21 Celgene Corporation Isotopologues of lenalidomide
AU2010229711B2 (en) 2009-03-25 2015-06-04 Anthrogenesis Corporation Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
PT2391355T (en) 2009-05-19 2017-02-21 Celgene Corp Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
JP5645816B2 (en) 2009-05-25 2014-12-24 国立大学法人東京工業大学 Pharmaceutical composition comprising core factor related to proliferation and differentiation of central nerve cell
CN101580501B (en) * 2009-06-01 2011-03-09 南京卡文迪许生物工程技术有限公司;严荣 Synthetic method of 3-(substituted dihydro-isoindolone-2-group)-2,6-dioxopiperidine and intermediate thereof
CA2773012A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Process for the preparation of lenalidomide
WO2011050962A1 (en) * 2009-10-29 2011-05-05 Ratiopharm Gmbh Acid addition salts of lenalidomide
CN102127054B (en) * 2009-11-02 2013-04-03 南京卡文迪许生物工程技术有限公司 3-(substituted dihydroisoindol-2-yl)-2,6-piperidinedione polymorph and pharmaceutical composite
CN101696205B (en) 2009-11-02 2011-10-19 严荣 3-(substituted xylylenimine-2-yl)-2,6-dioxopiperidine polymorph and pharmaceutical composition
WO2011069608A1 (en) * 2009-12-09 2011-06-16 Ratiopharm Gmbh S-lenalidomide, polymorphic forms thereof and blend comprising s- und r-lenalidomide
CA2783616A1 (en) 2009-12-22 2011-06-30 Celgene Corporation (methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
CA2786266A1 (en) 2010-01-05 2011-07-14 Celgene Corporation A combination of an immunomodulatory compound and an artemisinin or a derivative thereof for treating cancer
EP2536706B1 (en) 2010-02-11 2017-06-14 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
CA2794096A1 (en) 2010-04-07 2011-10-13 Celgene Corporation Methods for treating respiratory viral infection
US20140031325A1 (en) 2010-12-06 2014-01-30 Celgene Corporation Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
US8853175B2 (en) 2011-01-10 2014-10-07 Celgene Corporation Phenethylsulfone isoindoline derivatives and their use
HUE037955T2 (en) 2011-03-11 2018-09-28 Celgene Corp Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
CA2867134C (en) 2011-03-28 2019-05-07 Sheila Dewitt 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
US20140106390A1 (en) 2011-04-18 2014-04-17 Celgene Corporation Biomarkers for the treatment of multiple myeloma
CA2834535A1 (en) 2011-04-29 2012-11-01 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
WO2012177678A2 (en) 2011-06-22 2012-12-27 Celgene Corporation Isotopologues of pomalidomide
AU2012308663B2 (en) 2011-09-14 2017-06-08 Amgen (Europe) GmbH Formulations of cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
WO2013101810A1 (en) 2011-12-27 2013-07-04 Celgene Corporation Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
EP2817300B1 (en) * 2012-02-21 2018-04-25 Celgene Corporation Solid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
EP2858667A1 (en) 2012-06-06 2015-04-15 Bionor Immuno AS Hiv vaccine
EP2867671B1 (en) 2012-06-29 2018-10-24 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins
DK2882737T3 (en) 2012-08-09 2019-05-13 Celgene Corp Fast form of (s) -3- (4 - ((4-morpholinemethyl) benzyl) oxy) -1-oxoisoindolin-2-yl) piperidine-2,6-dione hydrochloride
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
JP2015534989A (en) 2012-10-22 2015-12-07 コンサート ファーマシューティカルズ インコーポレイテッド {S-3- (4-Amino-1-oxo-isoindolin-2-yl) (piperidine-3,4,4,5,5-D5) -2,6-dione} solid form
FR2999915B1 (en) * 2012-12-21 2017-08-11 Oreal Use of derivatives of imidocarboxylic acid as a soothing agent
FR2999914B1 (en) * 2012-12-21 2015-08-07 Oreal Use of imidocarboxylic acid derivatives for treating skin alterations related to age or photo aging
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
JP6359563B2 (en) 2013-01-14 2018-07-18 デュートルクス・リミテッド・ライアビリティ・カンパニーDeuteRx, LLC 3- (5-substituted-4-oxoquinazolin-3 (4H) -yl) -3-deuteropiperidine-2,6-dione derivatives
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
CN104072476B (en) * 2013-03-27 2018-08-21 江苏豪森药业集团有限公司 Pomalidomide crystal and its preparation method and application
AU2014254056B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and an IMiD compound for treating cancer
EP2815749A1 (en) * 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
CN103497174B (en) * 2013-07-29 2015-10-28 杭州派臣医药科技有限公司 Moor preparation and the process for purification of sharp degree amine
CN104557858B (en) * 2013-10-29 2018-06-01 上海医药工业研究院 A kind of preparation method of pomalidomide
CN107188884A (en) * 2013-10-29 2017-09-22 上海医药工业研究院 A kind of purification process of pomalidomide
PE20161030A1 (en) 2013-12-03 2016-11-06 Acetylon Pharmaceuticals Inc Combinations of histone deacetylase inhibitors and immunomodulatory drugs
CN104016967A (en) * 2014-04-04 2014-09-03 南京工业大学 Synthetic method of pomalidomide
JP2017528690A (en) 2014-06-27 2017-09-28 セルジーン コーポレイション Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
CN109678840A (en) * 2014-08-20 2019-04-26 河北菲尼斯生物技术有限公司 The preparation method of pomalidomide
EA201790439A1 (en) 2014-08-22 2017-07-31 Селджин Корпорейшн Methods of treating multiple myeloma with the use of immunomodulating compounds in combination with antibodies
CN105440013B (en) * 2014-08-29 2018-10-09 杭州和泽医药科技有限公司 A kind of preparation method of pomalidomide
JP6546997B2 (en) * 2014-10-30 2019-07-17 カンプー バイオファーマシューティカルズ リミテッド Isoindoline derivatives, intermediates thereof, production methods, drug compositions and applications
US10471156B2 (en) 2014-12-19 2019-11-12 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide
EP3233059A1 (en) 2014-12-19 2017-10-25 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide
CN104447689B (en) * 2014-12-22 2016-07-20 上海迈柏医药科技有限公司 Crystal formation of lenalidomide and preparation method thereof
US10001483B2 (en) 2015-06-26 2018-06-19 Celgene Corporation Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
MX2018007704A (en) 2015-12-22 2018-11-09 Synthon Bv Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant.
JP2019536460A (en) 2016-12-03 2019-12-19 ジュノー セラピューティクス インコーポレイテッド Regulation of CAR-T cells
CA3046869A1 (en) 2016-12-16 2018-06-21 Kangpu Biopharmaceuticals, Ltd. Combination, application thereof and treatment method
KR20190111133A (en) 2017-02-13 2019-10-01 강푸 바이오파마슈티칼즈 리미티드 Combinations, pharmaceutical compositions and methods of treatment for prostate cancer
SG11201910143TA (en) 2017-05-01 2019-11-28 Juno Therapeutics Inc Combination of a cell therapy and an immunomodulatory compound
US10093647B1 (en) 2017-05-26 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
AU2018275894A1 (en) 2017-06-02 2019-12-12 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
WO2019006427A1 (en) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
US10093649B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
US10093648B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
WO2019067792A1 (en) 2017-09-28 2019-04-04 Celularity, Inc. Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
WO2019089969A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
WO2019118937A1 (en) 2017-12-15 2019-06-20 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
EP3505158A1 (en) 2017-12-27 2019-07-03 KRKA, d.d., Novo mesto Pharmaceutical composition of lenalidomide pharmaceutically acceptable acid addition salt
WO2019164891A1 (en) 2018-02-21 2019-08-29 Celgene Corporation Bcma-binding antibodies and uses thereof
EP3545949A1 (en) 2018-03-29 2019-10-02 Midas Pharma GmbH Oral dosage forms comprising pomalidomide crystalline form a
WO2019199134A1 (en) 2018-04-13 2019-10-17 주식회사 삼양바이오팜 Pharmaceutical composition comprising lenalidomide
KR20190120095A (en) 2018-04-13 2019-10-23 주식회사 삼양바이오팜 Preparing method for oral solid formulation comprising lenalidomide
WO2019199132A1 (en) 2018-04-13 2019-10-17 주식회사 삼양바이오팜 Lenalidomide oral tablet composition in various amounts
KR20190120093A (en) 2018-04-13 2019-10-23 주식회사 삼양바이오팜 Oral Coated Tablet Formulation of Lenalidomide
KR20190120096A (en) 2018-04-13 2019-10-23 주식회사 삼양바이오팜 Oral tablet formulation of lenalidomide with improved disintegration

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014455A1 (en) * 1991-02-14 1992-09-03 The Rockefeller University METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
DE4422237A1 (en) * 1994-06-24 1996-01-04 Gruenenthal Gmbh Use of lactam compounds as pharmaceutical active ingredients
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
WO1998003502A1 (en) * 1996-07-24 1998-01-29 Celgene Corporation Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and method of reducing tnf-alpha levels

Also Published As

Publication number Publication date
DK0925294T6 (en) 2018-08-20
DE69739802D1 (en) 2010-04-22
PL195916B1 (en) 2007-11-30
HK1132502A1 (en) 2011-08-19
JP4065567B2 (en) 2008-03-26
KR100534498B1 (en) 2005-12-08
PT2177517E (en) 2011-11-10
KR20000068008A (en) 2000-11-25
CA2560523C (en) 2011-09-20
EP2070920A1 (en) 2009-06-17
EP2305663A1 (en) 2011-04-06
ES2339425T3 (en) 2010-05-20
FI990101D0 (en)
CN1117089C (en) 2003-08-06
CA2560523A1 (en) 1998-01-29
JP2001503384A (en) 2001-03-13
ES2529190T3 (en) 2015-02-17
AU3899897A (en) 1998-02-10
CA2624949C (en) 2011-02-15
CN1239959A (en) 1999-12-29
DE69717831T2 (en) 2003-08-28
AT500240T (en) 2011-03-15
EP2305663B1 (en) 2014-12-17
FI120687B1 (en)
CZ302378B6 (en) 2011-04-20
CZ20299A3 (en) 1999-06-16
ES2187805T7 (en) 2018-08-17
PT2070920E (en) 2011-03-31
AU715779B2 (en) 2000-02-10
HK1143360A1 (en) 2012-09-07
CZ295762B6 (en) 2005-10-12
EP1285916B1 (en) 2010-03-10
NZ333903A (en) 2000-02-28
HUS1300056I1 (en) 2016-08-29
AT460409T (en) 2010-03-15
DE69717831D1 (en) 2003-01-23
DE69717831C5 (en) 2008-03-20
EP0925294A1 (en) 1999-06-30
EP2070920B8 (en) 2011-04-27
DK0925294T3 (en) 2003-04-07
EP2070920B1 (en) 2011-03-02
PL191566B1 (en) 2006-06-30
ES2187805T3 (en) 2003-06-16
LU91359I2 (en) 2007-11-06
EP1285916A1 (en) 2003-02-26
FI120687B (en) 2010-01-29
DK1285916T3 (en) 2010-04-26
UA60308C2 (en) 2003-10-15
CZ304569B6 (en) 2014-07-09
DE69740140D1 (en) 2011-04-14
LU91359A9 (en)
FI990101A (en) 1999-03-19
NL300291I1 (en) 2007-11-01
HK1021819A1 (en) 2003-07-18
DE122007000079I2 (en) 2010-08-12
CA2624949A1 (en) 1998-01-29
PT1285916E (en) 2010-04-05
DK925294T3 (en)
ES2372577T3 (en) 2012-01-24
KR20050032629A (en) 2005-04-07
LU91359I9 (en) 2018-12-31
EP0925294B1 (en) 2002-12-11
CA2261762A1 (en) 1998-01-29
DE69717831T3 (en) 2018-08-30
HK1050893A1 (en) 2010-11-05
NL300291I2 (en) 2008-03-03
SK9199A3 (en) 1999-07-12
EP0925294B3 (en) 2018-07-04
AT229521T (en) 2002-12-15
PT925294E (en) 2003-04-30
WO1998003502A1 (en) 1998-01-29
CA2261762C (en) 2008-06-17
DE122007000079I1 (en) 2008-02-28
PL332867A1 (en) 1999-10-25
FI990101A0 (en) 1999-01-19
HK1153736A1 (en) 2015-09-18

Similar Documents

Publication Publication Date Title
DE69733111D1 (en) Kompositstent
DE69723121D1 (en) Rasiesystem
DK0901474T3 (en) Arylpyrimidinderivater
DE69717162T2 (en) Luftentstaubungsgerät
DE69737998D1 (en) Abgabevorrichting
DE69729887D1 (en) Purin-l-nucleosides, their analogs and uses
DE69722095T2 (en) Zinkoxyddispersionen
DE69736298D1 (en) Rekomprimierungsserver
DE69715959T2 (en) doppelzweckauflegewerkzeug
DE69739032D1 (en) Bandfixiervorrichtung
DK1114032T3 (en) 4-Amino-substituted-2-substituted-1,2,3,4-tetrahydroquinolines as CETB inhibitors
DE69714049T2 (en) Hochleistungsionomermischung
DE60139614D1 (en) Procedure for s.i.p / h.323 cooperation
DE69712689T2 (en) Prüfpunktrechnersystem
DK0973746T3 (en) Substituted 3-cyanoquinolines
DE69718119D1 (en) Verschlusskappe
DE69935206D1 (en) Theanin-legging composition
DE60028942D1 (en) Video coding
DE60020243D1 (en) Video coding
DK0958018T3 (en) Legetöjsbyggesætsystem
DE69827060D1 (en) Modified primers
DE69733008D1 (en) Chinazoline derivatives as antitum-agent
DE69739111D1 (en) Laserlichtreferenzierungswerkzeug
DK0912564T3 (en) Process for the preparation of tetrahydroimidazoquinolinamines.
DE60017101D1 (en) Azeotropähnliche compositions of 1,1,1,3,3-pentafluorbutane

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2177517

Country of ref document: EP